This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Comparing Ingrezza to Austedo as treatments for Tardive Dyskinesia
Ticker(s): NBIX, TEVAWho's the expert?
Institution: New York Medical College, SUNY
- Clinical Professor of Psychiatry and Behavioral Sciences at NY Medical College, clinical professor of psychiatry at SUNY Upstate Medical University, and adjunct clinical professor of psychiatry, Icahn School of Medicine at Mount Sinai.
- Currently a consultant in clinical trial design and interpretation frequent lecturer on the quantitative assessment of clinical trial results, including the metrics of number needed to treat and number needed to harm.
- Main interests include schizophrenia, bipolar disorder, and major depressive disorder.
Interview GoalThis call will examine the current treatment landscape for tardive dyskinesia, highlighting existing therapies such as Austedo (Deutetrabenazine) and their limitations. We will also discuss the potential of INGREZZA (valbenazine) as a transformative option, focusing on its efficacy, safety profile, and role in addressing unmet needs.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
